Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 P&L / Income Statement

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

2026-07-01 to 2026-09-30

Revenue by Business Segment by Geography

Swipe to see the full flow
Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 P&L / Income StatementIncome statement for 2026-07-01 through 2026-09-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETReportable Segment - UNITED STATESReportable Segment - Rest of WorldUndisclosed (calculated)Net revenueGross profitCost of salesOperating incomeTotal operating expensesOther income (expense), net (calculated)Income before income taxesNet incomeIncome tax expense (benefit)Other income (expense), net (calculated)Other income,net (calculated)$2.00 MIncome before income taxesPretax income$182.00 MNet revenueNet revenue$356.00 MGross profitGross profit$305.00 MOperating incomeOperating income$180.00 MNet incomeNet income$137.00 MReportable Segment - UNITED STATESReportable Segment - UNITED STATES$307.00 MTotal operating expensesTotal operatingexpenses$125.00 MIncome tax expense (benefit)Income taxexpense (benefit)$45.00 MReportable Segment - Rest of WorldReportable Segment - Rest of World$48.00 MCost of salesCost of sales$51.00 MUndisclosed (calculated)Undisclosed (calculated)$1.00 M
Chart details

Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 P&L / Income Statement

Income statement for 2026-07-01 through 2026-09-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenue
356,000,000 US dollars
Cost of sales
51,000,000 US dollars
Gross profit
305,000,000 US dollars
Total operating expenses
125,000,000 US dollars
Operating income
180,000,000 US dollars
Other income (expense), net (calculated)
2,000,000 US dollars
Income before income taxes
182,000,000 US dollars
Income tax expense (benefit)
45,000,000 US dollars
Net income
137,000,000 US dollars
Reportable Segment - UNITED STATES
307,000,000 US dollars
Reportable Segment - Rest of World
48,000,000 US dollars
Undisclosed (calculated)
1,000,000 US dollars
Selling, general and administrative
119,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Research and development
5,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
Indivior Pharmaceuticals, Inc. (INDV) FY2026 Q3 P&L / Income Statement Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!